Vishik Mehra
at Teladvice
Replay available
NGL Fine-Chem (NSE:NGLFINE) Q2 2027 earnings call, held 2026-11-12. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/ngl-fine-chem-limited-nglfine-q2-2027-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:02 Ladies and gentlemen, good day, and welcome to Q2 and H1 FY 'twenty seven Earnings Conference Call of NGL Fine Chem Limited. As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes.
0:24 Please note that this conference is being recorded. I now hand the conference over to Mr. Vishik Mehra from Teladvice. Thank you and over to you, Vishik. Thank you, Danish. Good morning, everyone and thank you for joining this Q2 and H1 FY 'twenty seven earnings conference call of NGL Fine Chem Limited. The results and investor updates have been uploaded on the stock exchanges. To take us through the results of the quarter and answer your questions, we have with us today Mr. Rahul Najne, Managing Director and Mr. Rajesh Ravande, Full Time Director and Chief Financial Officer.
0:55 We'll be starting the call with a brief overview of the financial performance, which will then be followed by the Q and A session. I would like to remind you that everything said in this call reflecting any outlook for the future, which can be construed as a forward looking statement, must be viewed in conjunction with the uncertainties and risks that the company faces. These uncertainties and risks are included, but not limited to what we have mentioned in our annual report. With that said, I'll now hand over the call to Mr. Rahul. Over to you, sir.
1:23 Good morning, everyone, and welcome to NGL Fine-Chem Limited's Q2 and H1 FY 'twenty seven earnings call. Thank you for joining us and for reviewing our financial results and investor presentation. Q2 was a strong quarter for NGL with higher revenues, improved operating profitability and continued volume growth. We also commenced production in Phase II of our Tarapore greenfield facility on 09/24/2026, completing the commissioning of the project. These developments give us greater confidence in the business. At the same time, commissioning marks the beginning of the next stage, building utilization, completing customer and regulatory requirements and earning an appropriate return on the investment.
2:09 Let me first take you through the through our consolidated financial performance. Revenue from operations for Q2 FY 'twenty seven was INR 158.71 crores, an increase of 32% over the corresponding quarter last year and 14% over Q1 FY 'twenty seven. The revenue also exceeded the 149.23 crore reported in Q4 FY 'twenty six. Growth continued to be led primarily by volumes, supported by demand across our product portfolio end markets. EBITDA increased by 64% year on year to INR 28.06 crore. The EBITDA margin was 17.68% compared with 14.27% a year earlier and 16.73% in the preceding quarter.
2:59 The improvement reflects the benefit of partial pass through price pass through to customers in Q1 and better absorption of fixed costs at higher volumes. The quarter's margin was within the 15% to 18% range we had indicated earlier. We are encouraged by this performance while recognizing that the cost of bringing the new capacity into cooperation will influence margins over the coming quarters. Profit before tax was INR 21.6 crores, an increase of 67% year on year. Profit after tax increased by 69% to INR 16.25 crores. On a sequential basis, profit after tax was lower than the INR 18.4 crores reported in Q1. This should be viewed alongside the change in other income, which declined from INR 7.43 crores to 1.2 crores and the increase in depreciation from INR 5.25 crores to INR 6.55 crores.
3:56 Q1 had also benefited from inventory gains and favorable ForEx movements, as discussed in our previous update. At the operating level, Q2 EBITDA increased by approximately 20% over Q1. The underlying improvement in the business is, therefore, stronger than the sequential movement in reported net profit alone would suggest. In the first half, revenue from operations was INR 297.87 crores, an increase of approximately 33% over H1 FY 'twenty six. Profit after tax was INR 34.64 crores compared with INR 18.87 crores in the corresponding period last year. Turning to cash flow and the balance sheet. Net cash from operating activities was INR35.8 crores in the first half.
4:45 Net investing outflows were INR44.05 crores as we continued expenditure towards completing the expansion.
4:53 Inventories increased from INR 70.28 crore at the end of March to INR 118.38 crore at the end of September. This reflects higher business activity and the stock required to support the new facility and our sales growth. Nevertheless, the increase is significant and working capital discipline will be an important priority as production and sales scale up.
5:17 Total borrowings were approximately INR122 crores compared with INR108 crores at the end of FY 'twenty six. Our focus now is on converting the investment in capacity and working capital into sales, operating cash flow and improved results. Coming to Tarapore, Phase II is operational and fully staffed. The facility provides flexibility to manufacture existing products and support products in our development pipeline. In the near term, we intend to use the capacity to serve demand in our existing markets while progressing the requirements for regulated market business. We currently expect utilization to reach approximately 30% to 40% over the next two to three quarters, subject to customer demand, product mix and the pace of production ramp up.
6:04 As utilization builds, the facility's fixed operating costs will spread over a larger production base. Initially, however, these costs will be incurred ahead of the full revenue contribution. Depreciation and finance costs will also affect reported earnings as the project moves fully into operation. We, therefore, expect some pressure on margins during this transition. Higher volumes should support earnings over time, but the pace of improvement will depend on utilization, realizations and operating efficiency.
6:36 Our regulatory program continues in parallel. In Europe, we have begun transferring the registrations to the new facility and currently target completion of this program by the end of calendar year 2027. Investors should distinguish completion of the overall transfer program from the timing of individual product approvals and customer orders. For The U. S, we have filed regulatory master files for nine products. Our customer is expected to complete their filings by December 2026. This is an important step in progressing the regulatory process, but the timing of an FDA inspection and subsequent commercialization remains dependent on the regulator, customer requirements and satisfactory completion of the applicable reviews.
7:22 We see regulated markets as a medium term growth opportunity.
7:26 Our immediate priorities are to execute the filings well, maintain inspection readiness and develop customer relations that can translate approvals into sustained business. Animal Health APIs remain the core of NGL, accounting for approximately 95% of revenue this year. Our top 10 customers contributed approximately 2026% of sales and our top 10 products approximately 65%. We will continue to build the business through our existing portfolio while developing additional products and customers.
8:01 Looking ahead, we remain cautiously optimistic. Demand has held up, operating performance has improved and the expanded manufacturing capacity gives us room to grow. The next few quarters will also require careful execution. Our priorities are to build utilization economically, manage working capital closely and progress regulatory and customer approvals. Pricing, input costs, currency movements and approval time lines will continue to influence the pace of improvement.
8:33 We believe NGL is better positioned to deliver profitable growth over the medium term. Our focus is on translating that opportunity into stronger cash generation and sustainable returns for shareholders. I thank you for your continued interest and support. I'll be now happy to take your questions.
8:54 Thank you so much, sir. Ladies and gentlemen, we will now begin with the question and answer session..
9:12 Also in order to ensure that the management will be able to address all the questions from the participant, we request you to kindly limit your question to two question only per participant. If you have a follow-up question, please rejoin the queue. Our first question comes from the line of Dhunil Desai with Total Capital. Please go ahead. Hi, good morning, sir, and congratulations for a very strong Q2 and commissioning of the entire facility. So my first question is, if we look at the P and L, you talked about incremental cost of employees and depreciation, finance and other operating costs coming through in subsequent quarters. But even this quarter, the employee and other expenses have kind of grown in line with revenue, which is around 30 odd
10:03 percent. So how should we look at what kind of incremental costs that will come through or are yet to come through? If you can elaborate on that, if like a large part is still to be coming flowing through in H2? That's my first question. And second question, sir, you talked about 30% to 40% utilization in next two to three quarters, which would probably be close to INR 1,100,000,000 odd crores of incremental revenue. So, while you talked about largely this coming through unregulated market, the regulated market picks up.
10:39 So once the regulated market picks up, how do we sustain this kind of unregulated market revenue? Do we have more CapEx plan for the unregulated market? Because eventually, we need capacity to solve that volume? These are the two questions. Yes. Thank you, Sunil. Employee costs have increased, as you have noted, in the current year also. That is because we started staffing part of our requirement in this quarter itself, and these people were being trained in our other plants.
11:20 And once they were fully trained, they were moved to the new project. So we have seen an increase in cost and there is likely to be a further increase in employee cost as we go forward also. With regard to we are currently seeing a good volume growth in our in the lesser regulated markets,
11:47 which are our current markets. And we would like to service this volume growth opportunity, which we have got by not losing any market share and serving our customers. To that extent, we are moving part of our requirement for these products into the new facility.
12:06 This will only occupy part of the facility and not the full facility as put forward, about 30% to 40% capacity utilization is what we expect. Going forward, as and when regulated market business starts coming in, we will be able to accommodate both these at least for the next three years in our opinion. And only if the requirement exceeds that, we'll review our
12:34 situation within a year's time and then decide whether we need to do further capital expansion.
12:41 I hope that answers your question. Sir, just one follow-up on this. Other expenses have almost moved in line with the revenue growth. And typically, other expenses have fixed and variable components to it. So do we see that going forward the incremental delta will be less than the revenue growth and hence the optimal level will continue to grow through? Is this how we should look at it?
13:13 In other expenses, main increment has been in fuel cost because we use gas for fuel in couple of our plants. And also with regard to the distribution expense because logistical costs have shot up in the last six months due to the Gulf War and transportation costs have close to double for us. So these are hopefully not in a of a fixed nature and should
13:45 regulate themselves over a period of time as the geopolitical political geographical situation improves. Got it. I have one question, but I will come back in the queue. You.
14:06 Our next question comes from the line of Ishaan Thakkar with Food Capital. Please go ahead. Yeah. Congratulations on a good set of numbers. Sir, last time you mentioned a possible price increase, but I believe it has not been implemented yet. So it is fair to say that the entire growth reported in Q2 was driven by volume growth
14:26 with no contribution from price increase? Is my understanding correct? Yes. Substantial part of it is from volume growth. Part of it is also because the rupee had weakened during that period against the dollar, but substantial part is due to volume growth. Okay. And as the price of Pularan has stabilized now, so what is the prevailing realized number kg? And how much incremental business opportunity do you see at the current price level?
14:57 So given that significant price erosion has already happened following competition, do you believe the current pricing is sustainable over the next two to three years? So what kind of volume growth and margin contribution can Pularaner generate for the company? Are you asking a specific question about a specific product? Yes, yes. Which product are you asking this for? Touraner, yes. Well, prices have come down. It's very difficult to predict what will happen in the future, but typically it is more of a historical trend that we see price decreases during the first two years of a product coming off patent and then it stabilizes.
15:49 It's already close to a year and half. So we feel that price erosion, if at all, would take place probably over the next six months and then it should start stabilizing. Okay. Okay. Got it. And one more question on U. S. And European markets. So our end user now started trial rounds and we currently have nine BMFs and four CAPs in place. So how is the initial response been so far? And by when do expect to see a meaningful contribution from these two markets to overall business? Well, see, the business is pretty slow normally. In Europe, our first filing the CP was granted close to about two years ago, and we are seeing some sprouts of business coming through now in the current year.
16:42 So the lead time is close to about two to three years from the time the filing is done. So it doesn't come so rapidly. We expect this to develop into a critical mass probably in the period of 2028 to 2030. Until then, we continue to focus on our existing markets and continue to fuel opportunities available there. Okay, okay. Okay. Thank you, sir. Thank you. Our next question comes from the line of Rahul Jain with Credit Suisse. Please go ahead. Thanks for the opportunity. Sir, congratulations to you and entire team at NGL for a wonderful set of results and wishing you all a very happy New Year.
17:35 My first question is with regards to the sales revenue and capacity utilization at the new plant. So we had mentioned in our previous call in quarter four, FY 'twenty six call that somewhere around INR 150 crores plus, we will stabilize in a quarter or two, and which we have done in this current quarter. At the same time, we have mentioned about utilizing about 30%, 40% for the new greenfield plant. So sir, just to understand, with regards to both these things, the current year, given that the new plant will also start contributing from the second half, So over and above that INR 150 crores, INR 155 crores of baseline sales, can we expect the current year second half to be much better than the first half, maybe we cross for the full year, say, around $6.30 crores to $6.50 crores of top line?
18:30 And what kind of utilization for the new greenfield do we expect for FY 'twenty eight? That is my first question. Shall I... Yes. I will answer this. As we have as I already set out earlier, we expect this capacity utilization over the next two to three quarters to reach between 3040% for the new plant, which has just recently been commissioned. And going forward, further capacity utilization is also dependent on what volume growth we can see in the current markets which we service. So it's very difficult to give an actual estimate for FY 2028.
19:25 But as you can see, the market has been moving well, demand is back in very well substantially And we have been able to meet and service this demand. Just to remind you, Phase one was already commissioned last year and we have been servicing part of the demand from Phase one already and that has contributed quite a bit to our ability to ramp up sales in the current year. Going forward, we are quite optimistic about how the market is moving. Well, we stick by what the guidance we had given earlier. So we are more or less on track for that.
20:13 Sure. Sir, with regard to the expense part, just to clarify, you did mention about increasing cost due to fuel transport and, of course, related to the environment, which is going on for last six months. We do understand that. But just plain, assuming those are normal, we had indicated an incremental operational cost of about INR 15 crores to INR 18 crores per annum basis and also the depreciation to increase by around INR 6 to 8 crores per year. So out of this, both operational cost, depreciation, what kind of cost has already been seen in quarter two? Or if I may put so, what incremental cost do we feel both on depreciation cost coming in based on the new plant?
21:04 And also if you could talk on the finance cost for the sale? So the finance cost, we don't anticipate a greater than a 20% increase from the current level. Depreciation, of course, as you had laid out, we have been capitalizing as and when things have been put to use. So over the current half year, which we have seen, we anticipate a further increase of not more than probably about 3 crores in depreciation cost. As far as operating cost is concerned, close to about 50% of our staffing is already done for the plant and we anticipate additional 50% more to come through for this project.
21:52 So we don't anticipate a huge increase in the manpower cost going forward. But OpEx cost will definitely go up and let us see how the margins shape up in the future. One last question, with regards to the inventory. Yes. We anticipate only for about the larger amount of pressure should not exceed beyond two to three quarters. Okay, okay. And sir, on the inventory side, we have inventory has increased in this current first half. There is a sizable increase on the inventory side. And also in terms of number of days also, it has increased. So is this inventory increase due to some kind of sales picking up ahead from the new plant or is it related to the validation batch inventories, if you could share some insights on the same?
22:59 We had moved about a year ago from manufacturing to order to manufacturing to stock and due to that strategy change, our inventory has been going up over the last five quarters. Having said that, there was also spurt in inventory because we anticipated some disruption which might come in to the unrest in the Gulf areas. So we increased our stocking of key raw materials, especially the ones with long delivery. So that these are the two primary reasons why inventory levels went up.
23:46 But going forward, Ryder, as we said, it has gone up a little further than what one would have anticipated. And we will be working towards better inventory controls to ensure streamlining of this going forward. Sure. Thank you so much and wish you all the best. Thank you. Thank you. Next question comes from the line of Dwanal Desai with Total Capital. Please go ahead. Hi. Thanks for the opportunity again, sir. Sir, in terms of EU filings, I think we had four approvals with us, right, on the CEP side.
24:39 And few I think five or six AFMS approvals. So any update on that? And I think we were targeting INR50, INR60 odd crores from Europe in the current year. So are we on track to that? And from that to let's say reaching INR100 odd crores, the part is what couple of years long or we see enough visibility to kind of get to that number in next year? Growth, the customer acquisition has not been as fast as we anticipated. It's taking between two to three years to get the customers on board after getting the regulatory approval.
25:26 So that has been a little slower than usual for us. So we might miss the target which we have set for ourselves for the current year, hopefully not by a very big margin. Going forward, as I said, we anticipate critical mass to develop only between 28 to 30. So that is where we expect most of our efforts to start being successful. Got it. Got it. And on the U. S. Side, you talked about customer filing to happen by December 26. And typically, I think earlier introduction, if I remember, six months is the timeline in which generally U. S. Inspection happens after filing. So but again, like it took slightly longer than our expectation on the Europe side.
26:18 Assume that there is specific customer related approvals which was available there. So in U. S. With customer filing on our VMF, does it mean that the ramp up part would be faster compared to Europe? Well, right now, we have one sponsor customer. So as you know, in Europe, we can go and register the product ourselves directly. We don't need any customer to intercede or come in between for that. In The U. S, it works differently. After it is filed, until a customer puts in a request and completes his filings, it does not trigger the requirement for an audit.
27:08 And until the plant is audited, it is not possible to do the sale into U. S. So we have been fortunate to have one sponsored customer who has supported us over the last full year. We have been working very closely with them and we are quite hopeful that once the approval once he files, it will trigger the requirement for an audit and of course, it's up to the regulatory agency to schedule and decide when to come and inspect. And that period can be anything from three months to a year. So we have to have patience for during that period. But this customer is very eager and we are very hopeful that once the regulatory approvals are in place, the sale will start quickly for that customer.
28:00 And having an approval will also give us sort of impetus because there are several customers who service both The U. S. And Europe markets together and quite a few of them are waiting to see how the U. S. Audit goes through. And then we are fairly confident that we'll be able to acquire those customers. Got it, sir. On the Europe side, sir, if you can give how many filings and how many approvals as on date? So, just give me a minute, I'll let you know. So we have four approvals for CEB and we have got four more products for which CEB has been filed.
29:00 We have five ASMF approvals as of now and four more have been filed. So that will make it a total of nine plus eight, 17 which are in the which have been filed, out of which nine are currently approved. And in terms of timeline, do we expect by next year we will get approval for all the 17 that we have filed for? By end of calendar year, next year, definitely, yes. Okay. Got it, Got it. And sir, last question. So on the U. S. Side, if I understand correctly, typically, it is our first inspection and now for the will be for the U.
29:50 S. FDA. So and it's not very easy to pass the inspection the first time. A lot of times, there is a possibility of observations and hence maybe follow-up inspection maybe six months later. So what are we doing from our side to ensure that we are able to kind of clear the U. S. FDA for the first time? What are the steps that we are taking? So we have got an experienced team in place, which have already have already faced U. S. Inspections and other regulatory inspections. We also have consultants on board who come and audit the facility every two months.
30:37 So our objective is to be always audit ready. So as and when this gets triggered, we should be ready for an audit at any point of time. Got it. Thank you and wish you all the best. Thank you. Our next question comes from the line of Rohit with Ithot PMS. Please go ahead. Yes, hello. Am I audible? Yes, sure. Good morning, sir, and congratulations on again a very good strong quarter. So just following up on a few questions that were asked earlier.
31:24 So you mentioned that this new plant will sort of get to a 3040% utilization in the next two to three quarters. So and that will be largely driven by the lesser regulated markets. So these are the new products these are the same products that we filed in Europe or these are the other new products that we have been sort of adding into RTT over the last two, three years, if you can maybe talk a bit about that? And also in the sense that the customers are the same or the customers in the sense that these customers are working in the lesser regulated market, but they're also in the regulated markets.
32:10 So if you can maybe talk a bit about that, the idea to get this question is to sort of understand the ramp up as and when happens in the regulated markets. Will this be while this has been slow so far, as you were saying, but as you sort of supply some of these products, will that sort of trigger the ramp up in EU specifically if the products are same and if the customers are same? So that was the first question. Yes. Well, most of the substantial part of our what we are moving now with new facility are products for which we have done the filings in Europe and also ones which we have planned on doing the filings for The U. S.
33:01 As I currently just set out earlier, there are close to 17 products which are either registered or under filed under the process of forum filing is completed. So we are concentrating on the in these 17 products, and these are also the top products by volume for us. So those are the ones which are being moved to this facility and not completely. We continue to manufacture at our existing facility also and incremental requirement is now getting moved to this new facility. Okay. So from a ramp up point of view, in especially EU and U. S, so next financial year or is it going to be in calendar year 2028 is when you see the big ramp up happening? Because as you said, this product would I mean U. S, I understand is largely dependent on the audit and that getting triggered in the subsequent audit.
34:00 But EU, which so far has been so reducing, like FY 2028 having some kind of a like what you had mentioned earlier, like around INR50 crores to INR100 crores kind of revenue from EU. So that do you think will happen in FY 2028? Well, see, it's still going a little slower than what we imagine it would in terms of getting approvals. So and on boarding customers, as I said, we anticipate the business to develop critical mass between '28 and '30. Okay. And sir, I'm assuming that your customers already will have some suppliers and we will be taking share away from them.
34:47 So like typically, what is the I I would assume our fit would be along with quality and regular supply reliable supply, would it be cost? And if so, how cheaper would BB versus their existing suppliers? And who these existing suppliers are maybe like which geography etcetera, if you can share some insights on that? The value proposition is not one standard and it changes with every customer. So to some customers, it is an opportunity to onboard a supplier with going forward registration both in EU and U.
35:33 S. Number two is giving a fully integrated chain of manufacturing backwards, which not very many companies do. Thirdly, to of course value proposition in terms of pricing has to be given forward to a few customers. So it's a mix of different things which we give forward. It just doesn't work on plain pricing. Right. Got it. And just final question on the margins. So I mean last two quarters we've been around that 17%, 18% operating margins And you've articulated in your opening remarks and in the presentation also that the costs are going to go up.
36:23 I mean, do you see these margins to be around the similar range around the 16%, 17%, 18%? Or it could be larger pressure because the ramp up also is going to be steep even if we were to do at a 3040% utilization only because that's almost close to INR130 crores, INR150 crores of revenue? Yes, see, we have always said that the long term margin in this industry is more close to 15% to 18% is what we will aim to achieve and we are currently in that slot. We feel that there might be a little bit of decrease as incremental costs come in, so there might be two or three quarters where we might see a little bit of dip in those margins.
37:12 But long term view is 15% to 18% is what we can expect from this business. Got it. Okay. Thank you very much. I'll join back. A couple of questions. You. Next question comes from the line of Raghuram Kuchi with Best Buzz Research and Advisory. Go ahead. Thanks for the opportunity sir and congrats on a good set of numbers. Sir, just wanted to know two things. One on the what could be the margins in the regulated market compared to our historical margin? Like how high would it be? Just not an exact guidance, but indication would be helpful, sir.
38:02 Well, margins are a little higher in regulated markets. If in the non regulated markets, if we can aim for between fifteen percent and eighteen I would guess in regulated markets, would be able to aim in terms of between 1822%. Okay. And on the existing like the non regulated markets, have been able to grow quite well over the last four quarters. So just wanted to understand like what is driving this growth because if you see in the last two, three two, three years back, This cyclical nature, again, would it do you see the sustaining the growth sustaining for the next one, two, three years or we cannot predict any of this for a two, three year period?
38:54 Well, last three years, which we saw mainly between 2023 and 2025, we saw dip in the market and that was more due to different reasons, as you can recollect. During COVID, sales rocketed up quite a bit. Customers end up stocking substantial amounts of quantities. And then between 2023 and 2025, there was the inventory decrease which took place on customers' books and therefore the demand had fallen down for the whole industry. Right now, we believe that, that particular scenario is now complete.
39:47 And going forward, we see very strong growth coming in this segment.
39:54 Do you foresee this growth over the next one to three years also, this high level? Pardon? You foresee this growth over the next you foresee this We feel the growth is quite substantial, meaning the market is growing currently at a good 10% to 12% internationally. Okay. And sir, on the regulated market business going forward, like what has changed structurally that we are able to able to be part of new customers? That is one question. Another thing is on the US FDA thing, like once we get a US FDA approval, can we keep adding additional DMFs there or every DMF will trigger a new US FDA approval request?
40:46 No. The U. S. FDA does not approve specific product filing. They approve the plant. So once your plant is approved, you keep on filing the DMFs. They will review the DMF, approve it. It does not trigger any additional audits.
41:07 Thanks, sir. Thanks a lot. That was helpful. All the best, sir. Thank you. Thank you. Our next question comes from the line of Rahul Jan with Credence Wealth. Please go ahead. Thanks for the opportunity again, sir. Sir, with regards to you did allude in last three quarters about the demand being very robust, demand continuously increasing and sales has consistent for more than three quarters now. And also to your previous participant, you did mention that after the tough year of 'twenty three to 'twenty five, we see a very strong growth going ahead. This growth momentum, you expect it to continue for next one off at least a year or so. So in your assessment, the prices have still not gone up after going down substantially in the last two, three years.
41:59 So going ahead, in your assessment, do you feel as the demand continues to remain strong, can we expect prices to have some uptick going ahead in say one or two quarters?
42:13 Is that a possibility? I don't see that possibility in the near future, no, at least not for the next three to five quarters, I don't see prices really going up. Okay, okay. Sure, sir. And with regards to further gross margin, again, after almost five, six quarters where our gross margins were around 50% for last two quarters, we have been clocking 56%, around 56% gross margins for last two quarters. So is this 55%, 56% gross margins which we have got for last two quarters now sustainable going ahead? I'm talking about gross margin. It's very difficult to say because the long term margin has been always been in the range of between 50% to 55%.
43:09 We are probably at better end of the spectrum currently. But going forward, it should remain within that range. So it can always move by a couple of percentage points up or down. Sure. But there is no one off in last two quarters, right? Is that understanding correct? No, there is no one off. It's been regular right now. Sure. And last question about debt, In terms of our debt, we have done reasonably well in terms of controlling our long term debt in spite of this large effect of INR $2.20 crores. But overall, both the long term and short term debt put together, do we feel that now that debt both long term and short term at peak or do you expect the debt to go up further given the increasing sales?
43:58 I expect short term debt to go up a little bit higher because with incremental turnover will require more infusion in for working capital funds, but definitely not any increase in the long term debt. Sure sir. Thank you so much again. You so much. Thank you. Next question comes from the line of Ula Guram Kuchi with Med Supplies Research and Enquiry LLP as a follow-up question. Please go ahead.
44:36 Sir, just for just one question, like in the regulated market, what are filings we have done, like you mentioned to the earlier participant that around 17 filings are the total that we will be doing in Europe and additional filings we will be doing in U. S. So can you just give us a sense of what is market size and what going forward, what market share we would be targeting? I'm not asking in the short term, but maybe from a three or five year perspective. What is the realistic achievable market share and the addressable market in EU and The U. S. Well, we are building up our regulatory book right now and regulatory approvals list.
45:24 So it's too early to talk about what market share we will obtain in these markets. Our objective right now is to register as many products as we can from our basket which we offer. And going forward, this gives us basically two distinct opportunities. Number one is that, a customer who requires multiple products can buy those multiple products from the same source because number of times customers are unwilling to move just for one single product because for them the compliance issues are quite substantial and they are not too willing to move. Secondly, we are also targeting not just the top five or top 10 companies, but we are trying to approach even smaller firms, which don't have a very wide basket, but or very large quantities.
46:28 But the idea is that our philosophy is that no customer is too small and we would like to service every point in this market. So are there any white spaces opening up because of some market structures changing, which is allowing us to target these opportunities, else? Because there is no easy way. There is no open space available, which we can just step in and start doing because it's quite a mature market. And most of the products which we do are have been out of patent for a substantial amount of time. So there are already existing supply lines. We have to work our way towards proving just offering a better value proposition.
47:20 Got it. Got it. Thank you, sir. Thanks. Thanks a lot. Thank you. As there are no further questions from the participant, now hand the conference over to Rahul, sir, for the closing remarks. Thank you and over to you, sir.
48:24 As there are no further questions from the participant, I now hand the conference over to the management for the closing remarks. Thank you and over to you, team. Yes. Thank you for joining us today and for your questions. We look forward to keeping you updated on our progress in the quarters ahead. Thank you. A Happy New Year and good day to all of you. Thank you so much, sir. Ladies and gentlemen, on behalf of NGL Fine Gap Limited, that concludes today's call. Thank you for joining us and you may now disconnect your line.
Follow NGL Fine-Chem Ltd. into a list and get an email when it puts out news.
at Teladvice
Managing Director at NGL Fine Chem Limited
Full Time Director and Chief Financial Officer at NGL Fine Chem Limited
at Total Capital
at Food Capital
at Credit Suisse
at Total Capital
at Best Buzz Research and Advisory
at Credence Wealth
at Med Supplies Research and Enquiry LLP